Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | February 15, 2025 | February 20, 2025 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director | June 04, 2024 | June 06, 2024 |
| Zenas BioPharma, Inc.ZBIO · Entity 275 | See Remarks | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date February 15, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,875 |
Ending reported balance
After 2025-02-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-02-15 · Exercise / conversion · Acquired 2,969 · Balance 35,384 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2025-02-15 · Exercise / conversion · Acquired 8,907 · Balance 44,291 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 3 · 2025-02-18 · Sale · Disposed 4,416 · Balance 39,875 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8376, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,750 |
Reported balance
After 2025-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-15 · Exercise / conversion · Disposed 2,969 · Balance 23,750 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,718 |
Reported balance
After 2025-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-15 · Exercise / conversion · Disposed 8,907 · Balance 26,718 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8376, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F5: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Tvardi Therapeutics, Inc.
Report date June 04, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,009 |
Reported balance
After 2024-06-04 transaction · row 1
1 source rowRow 1 · 2024-06-04 · Grant · Acquired 150,647 · Balance 183,009 F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2034-06-04 | Direct | 195,000 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Grant · Acquired 195,000 · Balance 195,000 F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Zenas BioPharma, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.71 · Expires 2036-06-15 | Direct | 150,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 150,000 · Balance 150,000 F1: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 17, 2026 22:02 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $18.71 | $0.00 |
DisclosureSEC source: 0001104659-26-075254 · tm2618042-6_4seq1.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-06-15 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:01 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001104659-25-035996 · tm2512517-1_4seq1.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-04-14 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on March 17, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 01:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,416 | $0.81 | $3,579.17 |
DisclosureSEC source: 0000950170-25-023569 · ownership.xml · nonDerivative · entry 3 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,875 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8376, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 8,907 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023569 · ownership.xml · derivative · entry 5 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,718 Underlying: Common Stock · 8,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,969 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023569 · ownership.xml · derivative · entry 4 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,750 Underlying: Common Stock · 2,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 8,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023569 · ownership.xml · nonDerivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023569 · ownership.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-017911 · ownership.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:20 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 977 | $0.54 | $528.26 |
DisclosureSEC source: 0000950170-24-128626 · ownership.xml · nonDerivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,415 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $0.5442, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:20 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,969 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128626 · ownership.xml · derivative · entry 3 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,719 Underlying: Common Stock · 2,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:20 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128626 · ownership.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 22:33 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,334 | $0.69 | $2,991.33 |
DisclosureSEC source: 0000950170-24-118424 · ownership.xml · nonDerivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,423 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on July 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F4 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.7011, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:33 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 13,744 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118424 · ownership.xml · derivative · entry 3 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,744 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:33 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 13,744 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118424 · ownership.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 21:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 973 | $0.84 | $817.32 |
DisclosureSEC source: 0000950170-24-098717 · ownership.xml · nonDerivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,013 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $0.890001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,969 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098717 · ownership.xml · derivative · entry 3 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,688 Underlying: Common Stock · 2,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-098717 · ownership.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001415889-24-015763 · form4-06062024_080647.xml · derivative · entry 2 von Moltke Lisa · CIK 0001808592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 150,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015763 · form4-06062024_080647.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,009 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:23 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,968 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062061 · ownership.xml · derivative · entry 3 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,657 Underlying: Common Stock · 2,968 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:23 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 939 | $0.94 | $882.66 |
DisclosureSEC source: 0000950170-24-062061 · ownership.xml · nonDerivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,017 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:23 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,968 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-062061 · ownership.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 16, 2024 Filed Feb 17, 2024 02:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,400 | $1.08 | $4,752.00 |
DisclosureSEC source: 0000950170-24-016690 · ownership.xml · nonDerivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,988 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 11,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016690 · ownership.xml · derivative · entry 6 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,625 Underlying: Common Stock · 11,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F7 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 11,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016690 · ownership.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 35,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016690 · ownership.xml · derivative · entry 5 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,625 Underlying: Common Stock · 35,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 287,905 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016690 · ownership.xml · derivative · entry 4 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,905 Underlying: Common Stock · 287,905 shares Expires 2034-02-13 F5 · derivative.exercise_date: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 213,750 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016690 · ownership.xml · derivative · entry 3 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,750 Underlying: Common Stock · 213,750 shares Expires 2034-02-13 F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,232 | $1.35 | $5,713.20 |
DisclosureSEC source: 0000899243-23-020070 · doc4.xml · nonDerivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,513 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on July 2, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3406 to $1.4115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 13,745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020070 · doc4.xml · derivative · entry 4 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,744 Underlying: Common Stock · 13,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 13,745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020070 · doc4.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:36 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 44,961 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-23-034341 · doc4.xml · derivative · entry 2 von Moltke Lisa · CIK 0001808592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,961 Underlying: Common Stock · 44,961 shares Expires 2033-06-01 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:36 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 32,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034341 · doc4.xml · nonDerivative · entry 1 von Moltke Lisa · CIK 0001808592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,362 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| April 27, 2023 Filed Nov 1, 2023 01:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 27,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020070 · doc4.xml · derivative · entry 3 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,489 Underlying: Common Stock · 27,489 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-23-004210 · doc4.xml · derivative · entry 2 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2033-02-02 F3 · derivative.exercise_date: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 47,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004210 · doc4.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 19, 2023 22:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 45,841 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-23-004068 · doc4.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,841 Underlying: Common Stock · 45,841 shares Expires 2033-01-02 F1 · derivative.exercise_date: The shares shall vest and become exercisable in twelve (12) equal quarterly installments beginning on November 1, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0000899243-22-005317 · doc4.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:53 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0000899243-21-005250 · doc4.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 20:18 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0000899243-20-010407 · doc4.xml · derivative · entry 1 von Moltke Lisa · CIK 0001808592 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2030-04-05 F1 · derivative.exercise_date: The option will vest as to 25% of the underlying shares on the first anniversary of April 6, 2020 and as to an additional 6.25% upon the completion of each three-month period of continuous service to the company thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.